Effects of Renal Denervation on Ambulatory Blood Pressure Measurements in Patients With Resistant Arterial Hypertension
暂无分享,去创建一个
C. Steinwender | H. Blessberger | M. Grund | A. Nahler | T. Lambert | V. Gammer | J. Kammler | Karim Saleh | K. Kerschner | Gunda Buchmayr
[1] R. Schmieder,et al. Ambulatory blood pressure monitoring: is it mandatory for blood pressure control in treated hypertensive patients?: prospective observational study. , 2013, International journal of cardiology.
[2] H. Krum,et al. Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension , 2013, Circulation.
[3] Jennifer Taylor,et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. , 2013, European heart journal.
[4] F. Leisch,et al. Redo of percutaneous renal denervation in a patient with recurrent resistant hypertension after primary treatment success , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[5] R. Schmieder,et al. Ruling out secondary causes of hypertension. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[6] G. Parati,et al. Updated ESH position paper on interventional therapy of resistant hypertension. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[7] G. Mancia,et al. Home and ambulatory blood pressure in resistant hypertension. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[8] M. Böhm,et al. Response and non-response to renal denervation: who is the ideal candidate? , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[9] D. Cohen,et al. Renal Denervation: A Potential New Treatment for Severe Hypertension , 2013, Clinical cardiology.
[10] Cheree James,et al. Autonomic markers of emotional processing: skin sympathetic nerve activity in humans during exposure to emotionally charged images , 2012, Front. Physio..
[11] Deepak L. Bhatt,et al. Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 Trial , 2012, Clinical cardiology.
[12] Gianfranco Parati,et al. The human sympathetic nervous system: its relevance in hypertension and heart failure. , 2012, European heart journal.
[13] M. Gawaz,et al. Effects of Renal Sympathetic Denervation on 24-hour Blood Pressure Variability , 2012, Front. Physio..
[14] M. Böhm,et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. , 2012, Journal of the American College of Cardiology.
[15] G. Bobrie,et al. Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension. , 2012, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[16] V. Somers,et al. Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea , 2011, Hypertension.
[17] R. Hermida,et al. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. , 2011, Journal of the American College of Cardiology.
[18] H. Krum,et al. Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study , 2011, Circulation.
[19] Symplicity Htn Investigators,et al. Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months , 2011, Hypertension.
[20] H. Krum,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.
[21] Guido Grassi,et al. Sympathetic neural activity in hypertension and related diseases. , 2010, American journal of hypertension.
[22] G. Dibona,et al. Translational medicine: the antihypertensive effect of renal denervation. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.
[23] Henry Krum,et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. , 2009, Hypertension.
[24] S. Julius,et al. The complex interaction between overweight, hypertension, and sympathetic overactivity. , 2009, Journal of the American Society of Hypertension : JASH.
[25] K. Kario,et al. 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes , 2009 .
[26] Michael Böhm,et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.
[27] A. Dominiczak,et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.
[28] Roberto Sega,et al. Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure , 2006, Hypertension.
[29] Paul A. Smith,et al. Relationship between central sympathetic activity and stages of human hypertension. , 2004, American journal of hypertension.
[30] G. Parati,et al. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis , 2004, Journal of hypertension.
[31] Peter W de Leeuw,et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. , 2003, The New England journal of medicine.
[32] G. Stergiou,et al. Reproducibility of home, ambulatory, and clinic blood pressure: implications for the design of trials for the assessment of antihypertensive drug efficacy. , 2001, American journal of hypertension.
[33] G Parati,et al. Ambulatory Blood Pressure Monitoring and Organ Damage , 2000, Hypertension.
[34] M. Kikuya,et al. Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study , 2000, Journal of hypertension.
[35] L. Ruilope,et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. , 1998, Hypertension.
[36] J. Born,et al. Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. , 1997, Hypertension.
[37] R. Kirkpatrick,et al. Ambulatory Blood Pressure Monitoring , 1993, The Journal of the American Board of Family Medicine.
[38] Julio A. Panza,et al. Circadian variation in vascular tone and its relation to α-sympathetic vasoconstrictor activity , 1991 .
[39] J. Laragh,et al. The reproducibility of average ambulatory, home, and clinic pressures. , 1988, Hypertension.
[40] W. Cooke,et al. Sympathectomy in the treatment of hypertension; review of 122 cases. , 1953, Lancet.
[41] H. Krum,et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. , 2012, Circulation.
[42] M. Gus. Renal sympathetic denervation in patients with treatment- resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial , 2011 .
[43] J. Manson,et al. Prospective Study of , 2007 .
[44] G. Bakris,et al. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. , 2006, American Heart Journal.
[45] Ettore Ambrosioni,et al. ESH/ESC guidelines for the management of arterial hypertension: how to implement in daily clinical practice , 2004 .
[46] A. Quyyumi,et al. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. , 1991, The New England journal of medicine.
[47] M. Elian,et al. Letter: Motor-neurone disease in Israel. , 1975, Lancet.